Details of the Drug
General Information of Drug (ID: DMOBIKY)
Drug Name |
Bexarotene
|
|||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Bexaroteno; Bexarotenum; Targret; Targretin; Targretyn; Targrexin; Bexarotene [USAN]; Elan brand of bexarotene;Ligand brand of bexarotene; LG 1069; LG100069; LG1069; LG69 compound; LGD 1069; LGD1069; LG-100069; LGD-1069; Targretin (TN); Targretin-gel; Bexarotene (USAN/INN); P-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid; 3-methyl-TTNEB; 4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl)benzoic acid; 4-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)benzoic acid; 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid; 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl]benzoic acid; 4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid; 4-[1-3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthaleneyl)vinyl]benzene carboxylic acid; 9RA
|
|||||||||||||||||||
Indication |
|
|||||||||||||||||||
Therapeutic Class |
Anticancer Agents
|
|||||||||||||||||||
Drug Type |
Small molecular drug
|
|||||||||||||||||||
Structure | ||||||||||||||||||||
3D MOL | 2D MOL | |||||||||||||||||||
#Ro5 Violations (Lipinski): 1 | Molecular Weight (mw) | 348.5 | ||||||||||||||||||
Topological Polar Surface Area (xlogp) | 7.6 | |||||||||||||||||||
Rotatable Bond Count (rotbonds) | 3 | |||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | |||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | |||||||||||||||||||
ADMET Property |
|
|||||||||||||||||||
Chemical Identifiers |
|
|||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Drug-Metabolizing Enzyme (DME) |
|
|||||||||||||||||||||||||||||||
Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||
Drug-Drug Interaction (DDI) Information of This Drug
Coadministration of a Drug Treating the Same Disease as Bexarotene
Coadministration of a Drug Treating the Disease Different from Bexarotene (Comorbidity)
|
Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug
References
1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2807). | ||||
---|---|---|---|---|---|
2 | Emerging drugs in cutaneous T cell lymphoma. Expert Opin Emerg Drugs. 2008 Jun;13(2):345-61. | ||||
3 | BDDCS applied to over 900 drugs | ||||
4 | Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds | ||||
5 | Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose | ||||
6 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | ||||
7 | Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. | ||||
8 | Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65. | ||||
9 | Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47. | ||||
10 | Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75. | ||||
11 | Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9. | ||||
12 | Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772. | ||||
13 | Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98. | ||||
14 | Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6. | ||||
15 | The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76. | ||||
16 | Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. | ||||
17 | Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9. | ||||
18 | Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4. | ||||
19 | Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98. | ||||
20 | Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076. | ||||
21 | Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30. | ||||
22 | New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126. | ||||
23 | A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7. | ||||
24 | A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63. | ||||
25 | Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4. | ||||
26 | The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. | ||||
27 | Farnesoid X receptor: from structure to potential clinical applications. J Med Chem. 2005 Aug 25;48(17):5383-403. | ||||
28 | The rexinoid LG100754 is a novel RXR:PPARgamma agonist and decreases glucose levels in vivo. Mol Endocrinol. 2001 Aug;15(8):1360-9. | ||||
29 | Phytanic acid is a retinoid X receptor ligand. Eur J Biochem. 1996 Feb 15;236(1):328-33. | ||||
30 | Co-regulator recruitment and the mechanism of retinoic acid receptor synergy. Nature. 2002 Jan 10;415(6868):187-92. | ||||
31 | Characterization of the interaction between retinoic acid receptor/retinoid X receptor (RAR/RXR) heterodimers and transcriptional coactivators thro... J Biol Chem. 2005 Jan 14;280(2):1625-33. | ||||
32 | Activation of mammalian retinoid X receptors by the insect growth regulator methoprene. Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):6157-60. | ||||
33 | Cerner Multum, Inc. "Australian Product Information.". | ||||
34 | Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14. [PMID: 12919179] | ||||
35 | Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA. | ||||
36 | Product Information. Targretin (bexarotene) Ligand Pharmaceuticals, San Diego, CA. | ||||
37 | Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261] | ||||
38 | Altice FL, Friedland GH, Cooney EL "Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone." AIDS 13 (1999): 957-62. [PMID: 10371177] | ||||
39 | Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY. | ||||
40 | Cerner Multum, Inc. "UK Summary of Product Characteristics.". | ||||
41 | Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ. | ||||
42 | Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ. | ||||
43 | Kivisto KT, Lamberg TS, Neuvonen PJ "Interactions of buspirone with itraconazole and rifampicin: Effects on the pharmacokinetics of the active 1-(2-pyrimidinyl)-piperazine metabolite of buspirone." Pharmacol Toxicol 84 (1999): 94-7. [PMID: 10068153] | ||||
44 | Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6. [PMID: 6953748] | ||||
45 | Product Information. Singulair (montelukast). Merck & Co, Inc, West Point, PA. | ||||
46 | Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ. | ||||
47 | Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ. | ||||
48 | Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ. | ||||
49 | Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN. | ||||
50 | Product Information. Aromasin (exemestane) Pharmacia & Upjohn, Kalamazoo, MI. | ||||
51 | Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35. [PMID: 2859674] | ||||
52 | Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
53 | Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8. [PMID: 9037249] | ||||
54 | Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ. | ||||
55 | Berthou F, Dreano Y, Belloc C, Kangas L, Gautier JC, Beaune P "Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes." Biochem Pharmacol 47 (1994): 1883-95. [PMID: 8204106] | ||||
56 | Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY. | ||||
57 | Bullman J, Nicholls A, Van Landingham K, et al. "Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers." Epilepsia 52 (2011): 1351-8. [PMID: 21635243] | ||||
58 | Bruderer S, Aanismaa P, Homery MC, et al. "Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist." AAPS J 14 (2012): 68-78. [PMID: 22189899] | ||||
59 | Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY. | ||||
60 | Crews KR, Stewart CF, Jones-Wallace D, et al "Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy." Clin Cancer Res 8 (2002): 2202-9. [PMID: 12114421] | ||||
61 | Faculty of Sexual & Reproductive Healthcare "FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.". | ||||
62 | Faculty of Sexual & Reproductive Healthcare "FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.". | ||||
63 | Product Information. Chirocaine (levobupivacaine) Organon, West Orange, NJ. | ||||
64 | Kharasch ED, Thummel KE "Human alfentanil metabolism by cytochrome P450 3A3/4. An explanation for the interindividual variability in alfentanil clearance?" Anesth Analg 76 (1993): 1033-9. [PMID: 8484504] | ||||
65 | Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ. | ||||
66 | Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA. | ||||
67 | Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA. | ||||
68 | Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT. | ||||
69 | Product Information. Brintellix (vortioxetine). Takeda Pharmaceuticals America, Lincolnshire, IL. | ||||
70 | Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61. [PMID: 7009137] | ||||
71 | Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83. [PMID: 9626925] | ||||
72 | EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.". | ||||
73 | Bittencourt PR, Gracia CM, Martins R, et al "Phenytoin and carbamazepine decrease oral bioavailability of praziquantel." Neurology 42 (1992): 492-6. [PMID: 1549207] | ||||
74 | Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT. | ||||
75 | Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA. | ||||
76 | Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC. | ||||
77 | Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL. | ||||
78 | Product Information. Cancidas (caspofungin) Merck & Co, Inc, West Point, PA. | ||||
79 | Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA. | ||||
80 | Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA. | ||||
81 | Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ. | ||||
82 | Borin MT, Chambers JH, Carel BJ, Gagnon S, Freimuth WW "Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate." Clin Pharmacol Ther 61 (1997): 544-53. [PMID: 9164416] | ||||
83 | Acosta EP, Henry K, Baken L, Page LM, Fletcher CV "Indinavir concentrations and antiviral effect." Pharmacotherapy 19 (1999): 708-12. [PMID: 10391416] | ||||
84 | Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC. | ||||
85 | Canadian Pharmacists Association. | ||||
86 | Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC. | ||||
87 | Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA. | ||||
88 | Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO. | ||||
89 | Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA. | ||||
90 | Borcherding SM, Baciewicz AM, Self TH "Update on rifampin drug interactions." Arch Intern Med 152 (1992): 711-6. [PMID: 1558427] | ||||
91 | Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ. | ||||
92 | Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL. | ||||
93 | Product Information. Lunesta (eszopiclone). Sepracor Inc, Marlborough, MA. | ||||
94 | Product Information. Sonata (zaleplon) Wyeth-Ayerst Laboratories, Philadelphia, PA. | ||||
95 | Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD. | ||||
96 | Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY. | ||||
97 | Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE. | ||||
98 | Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA. | ||||
99 | Cerner Multum, Inc. "Canadian Product Information.". | ||||
100 | Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626] | ||||
101 | Li J, Zhao M, He P, Hidalgo M, Baker SD "Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes." Clin Cancer Res 13 (2007): 3731-7. [PMID: 17575239] | ||||
102 | Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA. | ||||
103 | Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE. | ||||
104 | Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
105 | Product Information. Lariam (mefloquine). Roche Laboratories, Nutley, NJ. | ||||
106 | Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA. | ||||
107 | Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL. | ||||
108 | Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE. | ||||
109 | Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ. | ||||
110 | Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA. | ||||
111 | Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA. | ||||
112 | Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE. | ||||
113 | Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO. | ||||
114 | Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA. | ||||
115 | Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC. | ||||
116 | Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
117 | Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA. | ||||
118 | Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
119 | Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA. | ||||
120 | Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE. | ||||
121 | Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA. | ||||
122 | Product Information. Nuvigil (armodafinil). Cephalon Inc, West Chester, PA. | ||||
123 | Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA. | ||||
124 | Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA. | ||||
125 | Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John's Wort." Am J Med 112 (2002): 507-8. [PMID: 11959071] | ||||
126 | EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.". | ||||
127 | Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA. | ||||
128 | Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ. | ||||
129 | Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ. | ||||
130 | Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC. | ||||
131 | Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA. | ||||
132 | Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA. | ||||
133 | Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL. | ||||
134 | Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ. | ||||
135 | Product Information. Otezla (apremilast). Celgene Corporation, Summit, NJ. | ||||
136 | Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT. | ||||
137 | Pithavala YK, Tortorici M, Toh M, et al "Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers." Cancer Chemother Pharmacol 65 (2010): 563-70. [PMID: 19603168] | ||||
138 | Product Information. Nexavar (sorafenib). Bayer Pharmaceutical Inc, West Haven, CT. | ||||
139 | Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY. | ||||
140 | Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA. | ||||
141 | Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ. | ||||
142 | CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058] | ||||
143 | Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA. | ||||
144 | Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
145 | Jamis-Dow CA, Klecker RW, Katki AG, Collins JM "Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993. | ||||
146 | Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE. | ||||
147 | Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA. | ||||
148 | Product Information. Eliquis (apixaban). Bristol-Myers Squibb Canada Inc, Montreal, IN. | ||||
149 | Product Information. Cabometyx (cabozantinib). Exelixis Inc, S San Francisco, CA. | ||||
150 | Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL. | ||||